Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
FAIL · Does not pass the screen
5.28 USD
At the last full screen 2026-09-21
Screened 2026-09-21 · the tape above runs as of 23:00 UTC · 21 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 5.28 against the desk's fair-value range, base estimate 3.88, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price5.28 USD
Fair value3.88
Ethical score70.0/100
Our investment reviews on this name
2026-08-26Read Markdown4.62+14.3% to today
2026-07-02Read Distribution3.96+33.3% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cytek BioSciences Inc holds its Accumulation at $5.28. Consolidating, no directional conviction, held for 42 days.
As held on the ledger · 2026-09-21
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 42 days
Price at the screen
$5.28
Valuation
N/A trailing · 23.10 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.17
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.14%
Below 33%
Interest-bearing debt is just 5.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
36.98%
Below 33%
Interest-bearing cash and securities are 37.0% of assets, above the one-third limit.
Fail
Receivables
33.23%
Below 49%
Money owed to the company is 33.2% of assets, under the 49% limit.
Pass
Revenue purity
1.10%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 26.5% above the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits −1% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CTKB trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-26Markdown · changed$4.62+0.0%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-07-25Distribution$4.62+16.7%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 16.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-07-18Distribution$3.96+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6.
2026-07-03Distribution$3.96+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$3.96Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.